Literature DB >> 1970412

Lack of adverse reactions in ivermectin treatment of onchocerciasis.

G De Sole, K Y Dadzie, J Giese, J Remme.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1970412     DOI： 10.1016/0140-6736(90)92687-d

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.

Authors:  Mandy Juarez; Alejandro Schcolnik-Cabrera; Alfonso Dueñas-Gonzalez
Journal:  Am J Cancer Res       Date:  2018-02-01       Impact factor: 6.166

Review 2.  Tropical medicine.

Authors:  G C Cook
Journal:  Postgrad Med J       Date:  1991-09       Impact factor: 2.401

Review 3.  Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis.

Authors:  K L Goa; D McTavish; S P Clissold
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 4.  Onchocerciasis drug development: from preclinical models to humans.

Authors:  Adela Ngwewondo; Ivan Scandale; Sabine Specht
Journal:  Parasitol Res       Date:  2021-10-13       Impact factor: 2.289

5.  Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer.

Authors:  Shidong Lv; Zeyu Wu; Mayao Luo; Yifan Zhang; Jianqiang Zhang; Laura E Pascal; Zhou Wang; Qiang Wei
Journal:  Cell Death Dis       Date:  2022-09-01       Impact factor: 9.685
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.